Company Overview of Gen9, Inc.
Gen9, Inc. transforms synthetic biology by creating technologies for biopharmaceuticals, fine chemicals, and bio-fuels industries. It provides BioFAB for gene synthesis technologies and GeneBytes to enable gene-scale synthetic biology. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.
500 Technology Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Gen9, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2013.
Gen9, Inc. Key Developments
Gen9, Inc. Appoints Christopher Bruce as Vice President of Global Sales and Devin Leake as Vice President of Research & Development
Oct 9 13
Gen9, Inc. announced the appointment of Christopher Bruce, Vice President of Global Sales, and Devin Leake, Vice President of Research & Development. These additions underscore Gen9's commitment to expanding its global sales footprint and driving innovation in the high-throughput, automated production of DNA constructs at lower cost and higher accuracy. Bruce brings more than 25 years of sales and commercial leadership experience to Gen9. He joins the company from Cell Signaling Technology (CST) where he was most recently Sr. Director of Sales. In this role, he was responsible for developing the company's sales presence in the United States, and he facilitated the establishment of three international offices to expand CST's worldwide sales and marketing reach. Prior, Bruce worked for Invitrogen (Life Technologies), and Pierce (Thermo Fisher) as Director of Global Sales focused on developing sales strategy, sales channel management and distribution. Leake joins Gen9 from Thermo Fisher Scientific, where he was most recently Global Director of Molecular Biology R&D overseeing research in enzyme development and nucleic acid chemistry and biology. Before that, he worked at Dharmacon, an RNA synthesis company acquired by Thermo Fisher Scientific.
Gen9 Launches GeneBytes to Enable Gene-Scale Synthetic Biology
May 29 13
Gen9, Inc. announced the commercial availability of GeneBytes™ DNA constructs, or gene fragments, manufactured at lengths ranging from 1,000 to 3,000 base pairs long. This new capacity extends the company’s product portfolio, which also includes GeneBits™ constructs, shorter DNA snippets in the range of 500 to 1,000 base pairs. By the end of 2013, Gen9 plans to offer synthesized genes up to 10,000 base pairs long. Both GeneBits and now GeneBytes are produced as clonal, sequence-verified DNA and are shipped to the customer either as linear double-stranded DNA or cloned into vectors.
Gen9, Inc. Announces Board Appointments
Sep 25 12
Gen9, Inc. announced the newest members of its Scientific Advisory Board (SAB). In addition to advising the company on product development and future directions, SAB members will participate in selecting the winners of the G-Prize, which celebrates and supports innovation in the constructive application of synthetic DNA libraries. With its newest additions, the members of the company's Scientific Advisory Board include: David Baker, Professor of Biochemistry, University of Washington; Howard Hughes Medical Institute investigator; and elected to the National Academy of Sciences. George M. Church, Professor of Genetics, Harvard Medical School; Director of the Center for Computational Genetics; co-founder of Gen9, Knome, LS9; and elected to the National Academy of Sciences. Christopher Emig, Stanford University graduate student in bioengineering; former member, Codon Devices; winner of the David Adler Award for Outstanding Master's Degree in Electrical Engineering. Drew Endy, Assistant Professor of Bioengineering, Stanford University; Board president of the BioBricks Foundation; co-founder of the International Genetically Engineered Machines (iGEM) competition; and co-founder of the company. Joseph M. Jacobson, Associate Professor, Massachusetts Institute of Technology; co-PI of the Center for Bits and Atoms; leader of the Molecular Machine Group; co-founder of Gen9, E Ink, Kovio; and recipient of the 2000 Gutenberg Prize. Michael C. Jewett, Assistant Professor of Chemical and Biological Engineering, Northwestern University and recipient of the 2011 David and Lucile Packard Fellowship in Science and Engineering. Sriram Kosuri, Staff Scientist, Wyss Institute for Biologically Inspired Engineering and Harvard Medical School and co-founder of OpenWetWare, a website dedicated to the sharing of information in the biological sciences.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 22, 2013